Vertex Pharmaceuticals VRTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's operating income?
- Vertex Pharmaceuticals (VRTX) reported operating income of $1.14B in Q1 2026.
- How has Vertex Pharmaceuticals's operating income changed year-over-year?
- Vertex Pharmaceuticals's operating income increased by 80.6% year-over-year, from $630.1M to $1.14B.
- What is the long-term trend for Vertex Pharmaceuticals's operating income?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's operating income has grown at a 14.5% compound annual growth rate (CAGR), from $2.78B to $4.17B.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.